[go: up one dir, main page]

ZA200700779B - Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase and compositions and treatments using the same - Google Patents

Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase and compositions and treatments using the same

Info

Publication number
ZA200700779B
ZA200700779B ZA200700779A ZA200700779A ZA200700779B ZA 200700779 B ZA200700779 B ZA 200700779B ZA 200700779 A ZA200700779 A ZA 200700779A ZA 200700779 A ZA200700779 A ZA 200700779A ZA 200700779 B ZA200700779 B ZA 200700779B
Authority
ZA
South Africa
Prior art keywords
hepatitis
treatments
inhibitors
compositions
same
Prior art date
Application number
ZA200700779A
Other languages
English (en)
Inventor
Gonzalez Javier
Jewell Tanya Michelle
Li Hui
Linton Angelica
Tatlock John Howard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA200700779B publication Critical patent/ZA200700779B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200700779A 2004-08-18 2007-01-26 Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase and compositions and treatments using the same ZA200700779B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60261804P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
ZA200700779B true ZA200700779B (en) 2008-11-26

Family

ID=35429645

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200700779A ZA200700779B (en) 2004-08-18 2007-01-26 Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase and compositions and treatments using the same

Country Status (42)

Country Link
US (3) US7151105B2 (xx)
EP (1) EP1781662B1 (xx)
JP (1) JP4372195B2 (xx)
KR (1) KR100851178B1 (xx)
CN (2) CN101538268B (xx)
AP (1) AP2313A (xx)
AR (1) AR050699A1 (xx)
AT (1) ATE506364T1 (xx)
AU (1) AU2005273619B2 (xx)
BR (1) BRPI0514425A (xx)
CA (1) CA2577525C (xx)
CR (2) CR8935A (xx)
CY (1) CY1111480T1 (xx)
DE (1) DE602005027580D1 (xx)
DK (1) DK1781662T3 (xx)
EA (1) EA012605B1 (xx)
EC (1) ECSP077264A (xx)
ES (1) ES2361845T3 (xx)
GE (2) GEP20115305B (xx)
GT (1) GT200500221A (xx)
HN (1) HN2005000449A (xx)
HR (1) HRP20110458T1 (xx)
IL (2) IL180933A (xx)
MA (1) MA28803B1 (xx)
MX (1) MX2007001527A (xx)
MY (1) MY146123A (xx)
NI (1) NI200700043A (xx)
NL (1) NL1029755C2 (xx)
NO (1) NO20071274L (xx)
NZ (1) NZ552874A (xx)
PE (1) PE20060677A1 (xx)
PL (1) PL1781662T3 (xx)
PT (1) PT1781662E (xx)
RS (1) RS51794B (xx)
SI (1) SI1781662T1 (xx)
SV (1) SV2007002202A (xx)
TN (1) TNSN07066A1 (xx)
TW (1) TWI376379B (xx)
UA (1) UA88909C2 (xx)
UY (1) UY29068A1 (xx)
WO (1) WO2006018725A1 (xx)
ZA (1) ZA200700779B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2577525C (en) * 2004-08-18 2010-03-30 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
NZ565496A (en) * 2005-08-24 2010-10-29 Pfizer Methods for the preparation of HCV polymerase inhibitors
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
EP2008996A1 (en) * 2007-06-27 2008-12-31 Syngeta Participations AG Process for the production of pyrazoles
EP2280989B1 (en) 2008-06-06 2016-02-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
CN102176911B (zh) 2008-08-11 2014-12-10 葛兰素史密丝克莱恩有限责任公司 新的腺嘌呤衍生物
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
KR20110042116A (ko) 2008-08-11 2011-04-22 글락소스미스클라인 엘엘씨 알레르기성, 염증성 및 감염성 질환의 치료에서 사용하기 위한 푸린 유도체
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EP2325173A1 (de) 2009-11-19 2011-05-25 Bayer CropScience AG Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden
CN102753173A (zh) 2009-12-18 2012-10-24 贝林格尔.英格海姆国际有限公司 Hcv组合疗法
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
BR112012018904A2 (pt) 2010-02-10 2020-09-01 Glaxosmithkline Llc composto, adjuvante de vacina, composições imunogênica, de vacina e farmacêutica, e uso de um composto"
ES2528646T3 (es) * 2010-05-20 2015-02-11 Bayer Intellectual Property Gmbh Procedimiento para la fabricación de 1-alquil-3-difluorometil-5-hidroxipirazoles
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
FR2972452B1 (fr) 2011-03-09 2013-03-15 Rhodia Operations Procede de preparation du difluoroacetonitrile et de ses derives
JP6101345B2 (ja) 2012-05-14 2017-03-22 バイエル・クロップサイエンス・アクチェンゲゼルシャフト １−アルキル−３−フルオロアルキル−１ｈ−ピラゾール−４−カルボニルクロライド類の製造方法
EP2922548A4 (en) 2012-11-21 2016-06-01 Stategics Inc SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROPOLATION, DIFFERENTIATION AND OVER LIVING
BR112015015833B1 (pt) 2013-01-17 2020-05-19 Bayer Cropscience Ag processo de preparação de 5-fluoro-1 -metil-3-difluorometil-1 h-pirazol-4-carbaldeído
ES2656012T3 (es) 2013-02-06 2018-02-22 Bayer Cropscience Aktiengesellschaft Derivados de pirazol sustituidos con halógeno como pesticidas
KR20160104065A (ko) 2014-01-03 2016-09-02 바이엘 애니멀 헬스 게엠베하 농약으로서의 신규 피라졸릴헤테로아릴아미드
KR102319577B1 (ko) 2014-01-24 2021-10-29 바이엘 크롭사이언스 악티엔게젤샤프트 １-알킬-３-디플루오로메틸-５-플루오르-１ｈ-피라졸-４-카르브알데히드 및 １-알킬-３-디플루오로메틸-５-플루오르-１ｈ-피라졸-４-카르복실레이트의 제조 방법
WO2015124591A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
AU2015270118C1 (en) 2014-06-03 2019-11-28 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as T-type calcium channel blockers
US10584125B2 (en) 2014-11-13 2020-03-10 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
KR102419244B1 (ko) 2016-08-15 2022-07-08 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 축합 바이시클릭 헤테로사이클 유도체
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
TWI808952B (zh) 2016-12-16 2023-07-21 瑞士商愛杜西亞製藥有限公司 包含t型鈣通道阻斷劑之醫藥組合
CN110234622B (zh) 2017-02-06 2023-07-04 爱杜西亚药品有限公司 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法
US10981935B2 (en) 2017-10-04 2021-04-20 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
JP2020536106A (ja) 2017-10-05 2020-12-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
BR112020006780A2 (pt) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited moduladores do estimulador de genes do interferon (sting)
ES2929476T3 (es) 2018-03-12 2022-11-29 Bayer Ag Derivados heterocíclicos bicíclicos condensados como plaguicidas
US20210169080A1 (en) 2018-04-20 2021-06-10 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
KR102769633B1 (ko) 2019-01-25 2025-02-19 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 아실아미노 가교된 헤테로사이클릭 화합물, 및 이의 조성물 및 응용
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
EP3969452A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN112194620B (zh) * 2020-12-04 2021-02-26 苏州开元民生科技股份有限公司 一种2-乙基-4-氰基吡啶的制备方法
CN113563167B (zh) * 2021-07-16 2023-09-08 南通华祥医药科技有限公司 一种2-甲基-1-四氢萘酮的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) * 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
DE2155360C3 (de) * 1971-11-08 1980-04-03 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern
CA1140049A (en) * 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US4326058A (en) * 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) * 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US5504104A (en) * 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
RU2160733C2 (ru) * 1993-11-19 2000-12-20 Парк, Дэвис энд Компани Производные пирона и их фармацевтически приемлемые соли, промежуточные соединения для их получения, фармацевтическая композиция с антивирусной и антибактериальной активностью на их основе, способ лечения вызванных ретровирусом инфекции или заболевания
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
SI1142887T1 (en) 1993-11-19 2004-08-31 Parke, Davis & Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
NZ510013A (en) * 1998-09-11 2003-11-28 Warner Lambert Co Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors
US6512006B1 (en) * 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CA2577525C (en) * 2004-08-18 2010-03-30 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same

Also Published As

Publication number Publication date
KR100851178B1 (ko) 2008-08-08
AU2005273619B2 (en) 2009-05-28
US20060122399A1 (en) 2006-06-08
AU2005273619A1 (en) 2006-02-23
BRPI0514425A (pt) 2008-06-10
GEP20094751B (en) 2009-08-10
IL180933A (en) 2011-08-31
NL1029755A1 (nl) 2006-02-21
CR20110153A (es) 2011-04-26
ES2361845T3 (es) 2011-06-22
GEP20115305B (en) 2011-10-10
CN101538268A (zh) 2009-09-23
HK1109617A1 (en) 2008-06-13
CA2577525A1 (en) 2006-02-23
CY1111480T1 (el) 2015-08-05
AP2007003918A0 (en) 2007-02-28
RS51794B (sr) 2011-12-31
MX2007001527A (es) 2007-03-27
CA2577525C (en) 2010-03-30
UY29068A1 (es) 2006-03-31
ATE506364T1 (de) 2011-05-15
IL192919A0 (en) 2009-02-11
SI1781662T1 (sl) 2011-07-29
WO2006018725A1 (en) 2006-02-23
CN101538268B (zh) 2011-07-27
UA88909C2 (ru) 2009-12-10
PT1781662E (pt) 2011-07-01
EA012605B1 (ru) 2009-10-30
CN101006092A (zh) 2007-07-25
SV2007002202A (es) 2007-03-20
IL180933A0 (en) 2007-07-04
NZ552874A (en) 2010-04-30
JP2008509984A (ja) 2008-04-03
HRP20110458T1 (hr) 2011-07-31
CR8935A (es) 2007-07-24
US8268835B2 (en) 2012-09-18
EA200700338A1 (ru) 2007-08-31
AP2313A (en) 2011-10-31
ECSP077264A (es) 2007-04-26
PE20060677A1 (es) 2006-08-11
GT200500221A (es) 2006-06-21
PL1781662T3 (pl) 2011-08-31
NO20071274L (no) 2007-05-14
NL1029755C2 (nl) 2006-10-18
TWI376379B (en) 2012-11-11
US20070015764A1 (en) 2007-01-18
HN2005000449A (es) 2009-10-30
JP4372195B2 (ja) 2009-11-25
KR20070044057A (ko) 2007-04-26
TW200612898A (en) 2006-05-01
CN101006092B (zh) 2013-04-17
US7151105B2 (en) 2006-12-19
MY146123A (en) 2012-06-29
DK1781662T3 (da) 2011-06-27
NI200700043A (es) 2008-01-02
US7622605B2 (en) 2009-11-24
MA28803B1 (fr) 2007-08-01
AR050699A1 (es) 2006-11-15
US20090281122A1 (en) 2009-11-12
EP1781662A1 (en) 2007-05-09
TNSN07066A1 (fr) 2008-06-02
DE602005027580D1 (de) 2011-06-01
EP1781662B1 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
ZA200700779B (en) Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase and compositions and treatments using the same
AU2003224371A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007092888A3 (en) Hcv ns5b inhibitors
NL1025544A1 (nl) Remmers van rna-afhankelijk rna-polymerase van hepatitis-c-virus en preparaten en behandelingen waarbij ze worden gebruikt.
IL219150A0 (en) Viral polymerase inhibitors and pharmaceutical compositions comprising thereof
IL198248A0 (en) Hepatitis c virus inhibitors and compositions comprising the same
WO2004073599A3 (en) Inhibitors of hepatitis c virus, compositions and treatments using the same
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
SI1414441T1 (sl) Inhibitorji polimeraze virusa hepatitisa c, ki imajo heterobicikliäśno strukturo
ZA200607134B (en) Inhibitors of hepatitis C virus NS3 protease
AU2003256619A8 (en) Thionucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
HUP0400726A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
EP1766094A4 (en) INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE
AP2585A (en) Macrocyclic inhibitors of hepatitis C virus
AP2473A (en) Macrocyclic inhibitors of hepatitis C virus
IL182583A0 (en) 4-methoxymethyl-pyrrolidine-2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors
PL1912997T3 (pl) Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
IL188281A0 (en) Macrocyclic inhibitors of hepatitis c virus
IL197804A0 (en) Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
EP1450809A4 (en) NUCLEOSIDES, THEIR PREPARATION AND USE AS AN INHIBITORS OF RNA VIRUS POLYMERASES
HUE026600T2 (hu) Készítmények és eljárások virális hepatitis kezelésére
HK1095838A (en) Inhibitors of hepatitis c virus ns3 protease
HK1068796A (en) Nucleosides preparation thereof and use as inhibitors of rna viral polymerases